ADMA Biologics Inc (ADMA) Director Buys $53,750.00 in Stock
ADMA Biologics Inc (NASDAQ:ADMA) Director Eric I. Richman bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were acquired at an average price of $2.15 per share, with a total value of $53,750.00. Following the purchase, the director now owns 31,300 shares of the company’s stock, valued at $67,295. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
ADMA Biologics Inc (NASDAQ ADMA) traded down $0.08 on Monday, reaching $2.32. The company’s stock had a trading volume of 341,800 shares, compared to its average volume of 50,811. ADMA Biologics Inc has a 52 week low of $2.01 and a 52 week high of $6.88. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26.
ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.29). The firm had revenue of $3.40 million for the quarter, compared to analyst estimates of $3.52 million. ADMA Biologics had a negative return on equity of 76.26% and a negative net margin of 35.00%. equities analysts predict that ADMA Biologics Inc will post -2.25 earnings per share for the current fiscal year.
Separately, ValuEngine cut ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Stock Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related stocks with our FREE daily email newsletter.